Mount Sinai’s Department of Rehabilitation and Human Performance has announced a $6.2 million grant from the Steven & Alexandra Cohen Foundation.
Vivet wins $5.3m grant to develop gene therapy for rare metabolic disorder – Pharmaceutical Technology
Share this article Vivet’s VTX-806 is an adeno-associated virus (AAV) vector gene therapy that reinstates CYP27A1 gene activity. Image Credit: Anusorn Nakdee / Shutterstock. The French